US Stock Insider Trading | ADMA Biologics Discloses 3 Insider Transactions on February 23

K-LinePoet · 2026-02-27T11:28:27+00:00

ADMA Biologics disclosed multiple insider transactions on February 23, 2026, with major trades occurring on February 19 and February 17. Director Grossman Adam S sold nearly 46,000 shares on these two days, and other executives also engaged in stock transactions. The company focuses on developing biologics for immunodeficient patients.

K-LinePoet

2026-02-27 11:28:27

Abstract generation in progress

On February 23, 2026, ADMA Biologics (ADMA) disclosed three insider trading transactions. Director Grossman Adam S sold 24,800 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	Grossman Adam S	February 19, 2026	Sell	24,800	16.32	404,600
February 23, 2026	Executive	Kestenberg-Messina Kaitlin M.	February 19, 2026	Sell	8,161	16.32	133,200
February 23, 2026	Executive	Tade Brad L.	February 19, 2026	Sell	6,479	16.32	105,700
February 17, 2026	Director	Grossman Adam S	February 17, 2026	Sell	21,000	16.08	337,700
February 17, 2026	Director	Grossman Adam S	February 17, 2026	Buy	15,000	5.40	81,000
December 16, 2025	Director	Grossman Adam S	December 15, 2025	Buy	15,000	5.40	81,000
December 16, 2025	Director	Grossman Adam S	December 15, 2025	Sell	21,000	19.79	415,600
November 21, 2025	Director	Grossman Adam S	November 19, 2025	Buy	15,000	5.40	81,000
November 21, 2025	Director	Grossman Adam S	November 19, 2025	Sell	21,000	16.00	336,000
October 24, 2025	Director	Grossman Adam S	October 24, 2025	Buy	15,000	5.40	81,000

[Company Information]

ADMA Biologics, Inc. was incorporated in New Jersey on June 24, 2004. The company is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialized biologics for the treatment of immunocompromised patients at risk of infection and other individuals with specific infectious disease risks. The company’s target patient population includes individuals with potential immune deficiency diseases or those who may be immunosuppressed for medical reasons.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.